
Synthetic biology biotech nets three-hit combo in new financing, Bristol Myers deal and first CSO
A Bay Area biotech announced three new developments that have been in the works in recent months, hoping that all have a strong chance at propelling the company forward.
The first and newest development is the financing, as Octant — headed up by former UCLA professor Sri Kosuri and founded in 2017 — raised $80 million in a Series B round. It’s the biotech’s largest round to date, and more than doubles all its past fundraising combined, bringing its total financing so far to $115 million. Kosuri told Endpoints News that the funding gives Octant, which currently has around 50 employees, a cash runway of two to three years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.